Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12EKB | ISIN: CA09073K1084 | Ticker-Symbol: 20B
Frankfurt
06.06.25 | 08:02
0,187 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOMARK DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
BIOMARK DIAGNOSTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1870,25615:37

Aktuelle News zur BIOMARK DIAGNOSTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOMARK DIAGNOSTICS Aktie jetzt für 0€ handeln
21.05.Biomark Diagnostics Inc: Biomark publishes study examining AI in catching cancer2
20.05.BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology264Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer...
► Artikel lesen
13.05.Biomark Diagnostics Inc: Biomark's metabolomics tech discussed in study3
12.05.BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test237Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer...
► Artikel lesen
09.05.Biomark Diagnostics Inc: Biomark shares uplist to OTCQB Venture Market1
08.05.BioMark Diagnostics announces uplisting to OTCQB venture market3
08.05.BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Uplisting to OTCQB Venture Market198Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests...
► Artikel lesen
31.03.Biomark Diagnostics Inc: Biomark closes $4.26-million private placement1
31.03.BioMark Diagnostics, Inc.: BioMark Announces the Final Closing of Oversubscribed Private Placement280Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer...
► Artikel lesen
26.03.Biomark Diagnostics Inc: Biomark closes $2.88-million financing tranche1
26.03.BioMark Diagnostics, Inc.: BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform370Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, is...
► Artikel lesen
28.02.BioMark Diagnostics, Inc.: BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025402Vancouver, British Columbia--(Newsfile Corp. - February 28, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early...
► Artikel lesen
11.12.24Biomark Diagnostics Inc: Biomark talks breast cancer diagnostic capabilities4
10.12.24BioMark Diagnostics, Inc.: BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction411Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leader in liquid biopsy tests for early cancer detection...
► Artikel lesen
05.11.24BioMark Diagnostics, Inc.: BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection361Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early...
► Artikel lesen
24.09.24BioMark Diagnostics, Inc.: BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN444Vancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection...
► Artikel lesen
10.09.24BioMark Diagnostics, Inc.: BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection299Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection...
► Artikel lesen
26.08.24BioMark Diagnostics, Inc.: Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York586Vancouver, British Columbia--(Newsfile Corp. - August 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection...
► Artikel lesen
31.07.24BioMark Diagnostics, Inc.: The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay476Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - BioMark Diagnostics Inc., (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
15.07.24BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference665Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1